Combining PARP with ATR inhibition overcomes PARP inhibitor and platinum resistance in ovarian cancer models

Ovarian cancer (OVCA) inevitably acquires resistance to platinum chemotherapy and PARP inhibitors (PARPi). We show that acquisition of PARPi-resistance is accompanied by increased ATR-CHK1 activity and sensitivity to ATR inhibition (ATRi). However, PARPi-resistant cells are remarkably more sensitive to ATRi when combined with PARPi (PARPi-ATRi). Sensitivity to PARPi-ATRi in diverse PARPi and platinum-resistant models, including BRCA1/2 reversion and CCNE1-amplified models, correlate with synergistic increases in replication fork stalling, double-strand breaks, and apoptosis. Surprisingly, BRCA reversion mutations and an ability to form RAD51 foci are frequently not observed in models of acquired PARPi-resistance, suggesting the existence of alternative resistance mechanisms. However, regardless of the mechanisms of resistance, complete and durable therapeutic responses to PARPi-ATRi that significantly increase survival are observed in clinically relevant platinum and acquired PARPi-resistant patient-derived xenografts (PDXs) models. These findings indicate that PARPi-ATRi is a highly promising strategy for OVCAs that acquire resistance to PARPi and platinum.


Statistics
For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.
n/a Confirmed The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly The statistical test(s) used AND whether they are one-or two-sided Only common tests should be described solely by name; describe more complex techniques in the Methods section.
A description of all covariates tested A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals) For null hypothesis testing, the test statistic (e.g. F, t, r) with confidence intervals, effect sizes, degrees of freedom and P value noted Give P values as exact values whenever suitable.

For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes Estimates of effect sizes (e.g. Cohen's d, Pearson's r), indicating how they were calculated Our web collection on statistics for biologists contains articles on many of the points above.

Software and code
Policy information about availability of computer code Data collection

Data analysis
For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information.

Data
Policy information about availability of data All manuscripts must include a data availability statement. This statement should provide the following information, where applicable: -Accession codes, unique identifiers, or web links for publicly available datasets -A list of figures that have associated raw data -A description of any restrictions on data availability The statistical power for animal study is characterize in terms of effect size, defined as A/B, where A = the difference in mean tumor volume at a specific time in control mice compared to each of the treated groups, and B = the estimated pooled variance (in controls and treated mice) for the two groups being compared. An effect size over 1.0 is generally considered to be large, but can be expected to occur in well-controlled studies of treatments with relatively large effects on biological systems. With N = 10 mice per group, the probability is 0.56 of finding a statistically significant difference when treatment induces a difference of 1.0 standard deviation, and the probability is 0.89 of finding a statistically significant difference when treatment induces a difference of 1.5 standard deviations. To ensure statistical power in our results, we transplanted 12 mice per arm. After randomization, the majority of arms had 10 mice per arm with range 4-10.
For In vitro studies, "n" was chosen based on prior publications. No statistical model was used to predetermine the sample size. For in vitro experiments, 3-5 biological samples were tested in at least 3 independent experiments to draw a conclusion except for DNA combing studies where 2 independent experiments were performed. Two slides per condition were evaluated.
For in vitro studies, no data was excluded. For in vivo studies, mice that died for an unknown reason (low tumor burden, stable and normal weights, normal condition scores) would be excluded from analysis.
All in vitro studies were performed at least in three independent experiments. All conditions in each experiment had 3-5 biological replicates. All attempts at replication for in vitro experiments were successful. PDX expts were not repeated using the same model as this would not be acceptable by IUCUC.
For animal studies, mice were randomized to treatment groups using Tumor Manager (v 3.3.4) randomizing software by Biopticon. For In Vitro study, 3 biological replicates were randomly assigned to treatment groups. Cell cultures were randomly assigned to different groups or treatments.
For animal studies, weekly ultrasound measurements, weight assessments, and condition scores were obtained for treatment groups in a blinded manner. Histology was reviewed by pathologists and scored in a blinded manner.

Animals and other organisms
Policy information about studies involving animals; ARRIVE guidelines recommended for reporting animal research Laboratory animals